Compliance with herpes zoster vaccination in young and adult individuals in two regions of Italy

BMC Public Health

Volumn 10, Issue , 2010, Pages

  Parlato, Antonino ^a   Spica, Vincenzo Romano ^b   Ciccozzi, Massimo ^c   Farchi, Francesca ^c   Gallè, Francesca ^d   Di Onofrio, Valeria ^d   Franco, Elisabetta ^e   Liguori, Giorgio ^d  

^a Local Health Agency NA2   (Italy)

^b UNIVERSITY OF ROME FORO ITALICO   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

VARICELLA ZOSTER VACCINE;

ADOLESCENT; ADULT; ARTICLE; FEMALE; HUMAN; INTERVIEW; ITALY; MALE; PATIENT COMPLIANCE; QUESTIONNAIRE; STATISTICS;

ADOLESCENT; ADULT; FEMALE; HERPES ZOSTER VACCINE; HUMANS; INTERVIEWS AS TOPIC; ITALY; MALE; PATIENT COMPLIANCE; QUESTIONNAIRES; YOUNG ADULT;

EID: 77953303840     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-10-333     Document Type: Article

References (38)

1. Herpes zoster: epidemiology, natural history, and common complications. JM Weinberg, J Am Acad Dermatol 2007 57 130 S135 10.1016/j.jaad.2007.08.046 18021864
2. The nature of herpes zoster: a long term study and a new hypothesis. RE Hope-Simpson, Proc R Soc Med 1965 58 9 20 14267505
3. Population-based study of herpes zoster and its sequelae. MW Ragozzino LJ Melton LT Kurland CP Chu OH Perry, Medicine 1982 61 5 310 316 10.1097/00005792-198209000-00003 6981045
4. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. M Brisson WJ Edmunds B Law,, et al. Epidemiol Infect 2001 127 305 314 10.1017/S0950268801005921 11693508
5. What does epidemiology tell us about risk factors for herpes zoster? SL Thomas AJ Hall, Lancet Infect Dis 2004 4 26 33 10.1016/S1473-3099(03)00857-0 14720565
6. Current management of herpes zoster. The European view. A Volpi G Gross J Hercogova RW Johnson, Am J Clin Dermatol 2995 6 5 317 325 10.2165/00128071- 200506050-00005
7. Epidemiology of Varicella-Zoster virus in England and Wales. M Brisson WJ Edmunds, J Med Virol 2003 14 70 89
8. The Burden of Herpes Zoster and Postherpetic Neuralgia in the United States. BA Weaver, JAOA 2007 107 1 2 7
9. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. MN Oxman MJ Levin GR Johnson Shingles Prevention Study Group,, et al. N Engl J Med 2005 352 2271 84 10.1056/NEJMoa051016 15930418
10. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. MS Simberkoff RD Arbeit GR Johnson,, et al. Ann Intern Med 2010 152 9 545 54 20439572
11. The incidence of herpes zoster in a United States administrative database. RP Insinga RF Itzler JM Pellissier P Saddier AA Nikas, J Gen Intern Med 2005 20 748 753 10.1111/j.1525-1497.2005.0150.x 16050886
12. Incidence and hospitalization rates of varicella and herpes zoster before varicella vaccine introduction: a baseline assessment of the shifting epidemiology of varicella disease. P Coplan S Black C Rojas,, et al. Pediatr Infect Dis J 2001 20 641 645 10.1097/00006454-200107000-00002 11465834
13. Epidemiology and natural history of herpes zoster and postherpetic neuralgia. RH Dworkin KE Schmader, Herpes zoster and postherpetic neuralgia New York: Elsevier Press, Watson CPN, Gerhon AA, 2001 39 64
14. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. K Schmader JW Gnann Jr CP Watson, J Infect Dis 2008 197 1 207 15 10.1086/522152 (Pubitemid 351590173)
15. Epidemiology of severe varicella-zoster virus infection in Spain. M Gil A Sanmartin P Carrasco A Gonzales, Vaccine 2004 22 3947 51 10.1016/j.vaccine. 2004.04.004 15364443
16. Epidemiology and costs of herpes zoster: background data to estimate the impact of vaccination. V Di Legami MM Gianino MC Atti M Massari A Migliardi GS Tomba C Zotti Group Zoster Study, Vaccine 2007 25 43 7598 604 10.1016/j.vaccine.2007.07.049 17889410
17. Varicella zoster vaccines. R Creed A Satyaprakash P Ravanfar, Dermatol Ther 2009 22 2 143 9 10.1111/j.1529-8019.2009.01226.x 19335725
18. FDA approve Schingles Vaccine - Herpes Zoster Vaccine targets older adults. M Mitka, Medical News and Perspectives 2006 296 157
19. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. JM Pellissier M Brisson MJ Levin, Vaccine 2007 25 49 8326 37 10.1016/j.vaccine.2007.09.066 17980938
20. Prevention of Herpes Zoster. Recommendations of the Advisory Committee on Immunization Practices (ACIP). R Harpaz IR Ortega-Sanchez JF Steward, MMWR 2008 57 1 30 18528318
21. Active immunoprophylaxis to reduce clinical impact of Herpes Zoster and its complications. MG Marino B Bagnato I Torella E Franco, Ig Sanita Pubbl 2009 65 3 299 311 19629155
22. The impact of the varicella vaccination program on herpes zoster epidemiology in the United States: a review. MA Reynolds SS Chaves R Harpaz AS Lopez JF Seward, J Infect Dis 2008 197 1 224 7 10.1086/522162 (Pubitemid 351590175)
23. Perspective on live varicella vaccine. AA Gershon SL Katz, J Infect Dis 2008 197 2 242 5 10.1086/522151 (Pubitemid 351590178)
24. Prevention of varicella and zoster by live attenuated VZV vaccine. S Hambleton, Front Biosc 2008 13 2696 704 10.2741/2876 (Pubitemid 351599713)
25. Vaccination strategies for the prevention of Herpes zoster and postherpetic neuralgia. RF Betts, J Am Acad Dermatol 2007 57 6 143 7 10.1016/j.jaad.2007.09.017 (Pubitemid 350087359)
26. Prevention strategies: herpes zoster, post-herpetic neuralgia and immunogenicity. MJ Levin K Shmader, Herpes 2007 14 2 45 7 17939896
27. Vaccination to prevent herpes zoster in older adults. JW Gnann, J Pain 2008 9 1 31 6 10.1016/j.jpain.2007.10.007 (Pubitemid 350309524)
28. Preventing herpes zoster through vaccination. LD Gelb, Ophtalmology 2008 115 2 35 8 10.1016/j.ophtha.2007.10.015 (Pubitemid 351173975)
29. It is possible to prevent herpes zoster through vaccination? E Franco L Zaratti S Ambrosini Spinella, Ig San Pubbl 2007 63 2 191 5
30. Community and patient values for preventing herpes zoster. TA Lieu I Ortega-Sanchez GT Ray,, et al. Pharmacoeconomics 2008 26 3 235 49 10.2165/00019053-200826030-00006 18282017
31. Herpes zoster and vaccination: a clinical review. EN Adams S Parnapy P Bautista, Am J Health Syst Pharm 2010 67 9 724 7 10.2146/ajhp090118 20410546
32. A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK. L Moore V Remy M Martin M Beillat A McGuire, Cost Eff Resour Alloc 2010 8 1 7 10.1186/1478-7547-8-7 20433704
33. The impact of varicella vaccination in the United States. S Hambleton AA Gershon, Semin Pediatr Infect Dis 2005 16 38 43 10.1053/j.spid.2004.09.010 15685148
34. Family history as risk factor for herpes zoster. LD Hicks RH Cook-Norris N Mendoza V Madkan A Arora S Tyring, Arch Dermatol 2008 144 5 603 8 10.1001/archderm.144.5.603 18490586
35. Safety and immunogenicity profile of the concomitant administration of Zostavax and inactivated influenza vaccine in adults aged 50 and older. B Kerzner AV Murray F Cheng,, et al. J Am Geriatr Soc 2007 55 10 1499 507 10.1111/j.1532-5415.2007.01397.x 17908055
36. The prevention and management of herpes zoster. AL Cunningham J Breuer DE Dwyer,, et al. Med J Aust 2008 188 3 171 6 18241179
37. Public Awareness and Knowledge of Herpes Zoster: Results of a Global Survey. E Paek R Johnson, Gerontology 2010 56 1 20 31 10.1159/000240046 19776543
38. Determinants of non-compliance with herpes zoster vaccination in the community-dwelling elderly. W Opstelten GA van Essen E Hak, Vaccine 2009 27 2 192 6 18996427